Oxidosqualene cyclases (OSC) areenzymes involved incyclization reactions of2,3-oxidosqualene to formsterols ortriterpenes.[1]
There are two major groups of sterol-producing OSC enzymes:
Sterols and triterpenes are extremely diverse classes ofnatural products, particularly in plants, which often contain numerous OSC enzymes with different substrate and product specificities;[1] common examples includelupeol synthase andbeta-amyrin synthase.[2] OSC enzymes'catalytic mechanism is similar to the prokaryoticsqualene-hopene cyclase.[3]
Directed evolution andprotein design have been used to identify small numbers ofpoint mutations that alter the product specificities of OSC enzymes, most notably in altering a cycloartenol synthase to produce predominantly lanosterol.[4]
Oxidosqualene cyclase is amonomeric enzyme. Its active site consists of a depression between two barrel domains.[5] The active site is mostly made up of acidic amino acids in the majority of organisms.[6] The residues in the active site make it energetically favorable for oxidosqualene to take on a more folded conformation, which closely resembles its product.[5] This crucially sets the substrate up for the series of reactions that form the rings. Oxidosqualene is located in the cell’smicrosome membranes where it can easily harvest its hydrophobic substrate and turn out its hydrophobic product.[7]
Oxidosqualene cyclases produce a wide range ofsterols andtriterpenes.[1] In animals and fungi, the type known asLanosterol synthase produceslanosterol, which is then converted through many steps intocholesterol.[8] Products produced by other types of the enzyme includecycloartenol,lupeol,beta-amyrin, and many more.[2]
The enzyme’s genetic expression in animals is regulated bysterol regulatory element binding protein (SREBP-2), a molecule which also regulates the expression of other enzymes in the cholesterol biosynthesis pathway.[9] The SREBP-2 transcription factor increases enzymatic activity upstream of OSC, such as that ofHMG-CoA reductase andsqualene synthase, to increase flux through sterol synthesis process.[10]
Mechanistically, the enzymeoxidosqualene:lanosterol cyclase catalyzes the formation of four rings along the long chain of the substrate (oxidosqualene), producing lanosterol. This cyclization is one of the most complex known enzyme functions[11] and is highly selective.[12] The reaction can be characterized by two main mechanistic series: anepoxide ring opening followed by a series of ring closures and a series of 1,2-hydride and 1,2-methyl shifts. These mechanistic steps are catalyzed by a collection of amino acids in the active site.[13]
In the enzyme’s active site, ahistidine residue activates anaspartic acid residue (which has been identified as Asp455),[13] which protonates the substrate’s epoxide, setting off a series of carbon-carbon bond formations that form rings.[7][14] More specifically, this ring closure occurs ring by ring (labeled A-D in the mechanism below). It is widely accepted that the epoxide protonation is concurrent with the A ring closure.[15] The cation is then transferred from C10 to C8 to form the B ring.[15] It is the C ring formation that puzzles scholars. However, recent studies have come to a conclusion that the ring is first closed via aMarkovnikov addition, forming a 5-carbon intermediate.[15] Following this, the D ring is formed, pushing out the C ring to its 6-carbon final state.[15] To note,QM/MM studies have shown that the protonation of this epoxide ring is the rate limiting step of the entire mechanism,[13] indicating it may be the most regulated.
The intermediate formed after the four ring closures undergoes two1,2-hydride shifts and two1,2-methyl shifts to be in position for final de-protonation.[16] Molecular dynamics simulations have proved critical to understanding the conformational changes that oxidosqualene-lanosterol intermediates undergo.[16] Researchers have identified Phe696 as a critical amino acid for controlled and specific hydride shifting in this mechanism (steps 5-6), as it speeds up the shift by lowering the energy barrier of the respective transition states.[16]
Finally, the enzyme de-protonates to yield lanosterol, which has ahydroxyl group instead of anepoxide. This hydroxyl group can be seen in theimage above. The literature has shown that two amino acids in OSC are critical for this de-protonation to occur correctly and uniformly. Tyrosine at the 503rd position works in tandem with histidine at the 203rd position to de-protonate the hydrogen at the carbon adjacent to the carbocation in intermediate 8.[13] This is accomplished as shown in the proposed mechanism below. The crystal structure of the OSC-lanosterol complex confirms that Tyr503 and His232 are in optimal positions for this final de-protonation step.[13]
High blood cholesterol, also calledhypercholesterolemia, significantly increases the risk of stroke, heart attack, and peripheral artery disease. If untreated, it can also lead to plaque accumulation in blood vessels, which is known as atherosclerosis.[17] For this reason, the sterol biosynthetic pathway has long been a target for the drug development industry.Statins, which inhibitHMG-CoA reductase (an enzyme that catalyzes an earlier step in the cholesterol biosynthesis pathway) are commonly prescribed to treat high cholesterol. Research is being done for other compounds which block different steps in thebiosynthesis of cholesterol, including the reaction performed by oxidosqualene cyclase which cyclizes squalene to form lanosterol.[7] Oxidosqualene cyclase, which is downstream of squalene in the pathway, is an attractive target for inhibition. Many inhibitors have been proposed, among them steroid analogs, phenol-based compounds, benzamide and carboxamide derivatives, and nitrogen-containing heterocyclic compounds. The most effective inhibitors have a hydrogen-bond acceptor at a specific distance away from a hydrophobic region.[6]
Inhibitors of oxidosqualene cyclase have shown promise as antimicrobial agents as well, because they’ve been shown to kill offTrypanosoma cruzi.[18][19]Trypanosoma cruzi is a parasite transmitted to people by insects, mostly in Latin America. The parasite causes a disease calledChagas disease, in which acute infections around an insect bite can lead to more serious complications, such as decreased heart, esophagus, colon, and even brain function.[20] Another parasite,Leishmania donovani, is the causative agent forleishmaniasis, a similar tropical disease that is spread bysand flies and disproportionately affects rural areas.[21] GSK2920487A, a cyclic and aromatic small molecule, has been shown to significantly inhibit oxidosqualene cyclase and decrease the survival of theL. donovani.[22] While there is concern that parasites such asT. cruzi andL. donovani are able to scavenge the sterol compounds that oxidosqualene cyclase catalyzes the formation of, the potency of chemical inhibition against this vital enzyme demonstrate the potential of OSC as a therapeutic target.
Stork, et al. compared the protein sequences ofC. albicans oxidosqualene cyclase with the analogous enzyme (squalene cyclase) in two different bacteria and foundconserved regions in the former.[23] Rabelo et al. found a conserved active site across seven organisms.[6] The specific function and regulation of OSC seems to deviate even among eukaryotes. For example, OSC in both mammals and yeast are accompanied by a ketoreductase protective enzyme. However, this enzyme is necessary for OSC function in yeast only, suggesting the divergent evolution of the steroid biosynthesis pathway in mammals.[24] It is believed that animal and fungal oxidosqualene cyclases likely evolved from their prokaryotic counterparts.[23]
While the biosynthetic steps and catalytic amino acids of human OSC have been characterized, less is known about OSC specificity in other kingdoms of life. For example, theoomyceteSaprolegnia parasitica, afish pathogen, possesses a unique amino acid triad present in only some plant LAS enzymes, though the triad is responsible for determining CAS of LAS specificity in this class of organisms.[25]
